The US Food and Drug Administration may be willing to clear Iterum Therapeutics plc’s oral uncomplicated urinary tract infection (uUTI) treatment, if labeling can be written to guide physicians toward appropriate use and minimize the threat of antimicrobial resistance or cross-resistance to other carbapenems.
Key Takeaways
-
Iterum’s pivotal studies may be enough for a favorable benefit-risk balance, but not necessarily a label that offers key marketing advantages, such as use in patients who show signs of resistance to other uUTI treatments.
-
The FDA’s decision to have no advisory committee vote on the NDA may be an indication that the agency is implementing panel reforms stakeholders oppose
None of the flaws FDA outlined in the preview documents for sulopenem etzadroxil/probenecid's 9 September Antimicrobial Drugs Advisory Committee seem like clear dealbreakers for the application’s second review, but determining where the drug fits among other uUTI options and ensuring proper stewardship could be challenging
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?